Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Indaptus Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
INDP
Nasdaq
2830
indaptusrx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Indaptus Therapeutics, Inc.
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
- Feb 5th, 2025 1:00 pm
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Jan 13th, 2025 1:00 pm
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
- Jan 8th, 2025 1:00 pm
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
- Nov 22nd, 2024 1:36 pm
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov 12th, 2024 1:00 pm
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
- Nov 11th, 2024 1:00 pm
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
- Nov 7th, 2024 1:00 pm
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
- Oct 23rd, 2024 12:00 pm
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
- Oct 22nd, 2024 12:00 pm
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data
- Oct 15th, 2024 12:00 pm
Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy
- Oct 10th, 2024 12:00 pm
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
- Oct 8th, 2024 12:00 pm
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
- Sep 5th, 2024 12:30 pm
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 3rd, 2024 12:00 pm
Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Aug 12th, 2024 12:00 pm
Insider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2m
- Aug 11th, 2024 2:05 pm
Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement
- Aug 7th, 2024 11:00 am
Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit
- Jun 11th, 2024 12:00 pm
Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
- Jun 4th, 2024 12:00 pm
Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
- Jun 3rd, 2024 12:00 pm
Scroll